Testing a diabetes self-management program with glucose sensors in adults with type 2 diabetes
Tests a virtual self-management program plus glucose sensors in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Feasibility of a Diabetes Self-Management Program With Continuous Glucose Monitoring for Adults With Type 2 Diabetes
Key facts
- Where
- Manhasset, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and a high blood sugar marker (hemoglobin A1C of 8.0% (64 mmol/mol) or greater). They will join a 9-week virtual diabetes program and wear a glucose sensor.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with a hemoglobin A1C of 8.0% (64 mmol/mol) or greater on a lab result from the past 3 months.
- Earlier treatment
- People currently using continuous glucose monitoring (CGM) cannot join.
- Biomarker or test result
- Hemoglobin A1C of 8.0% (64 mmol/mol) or greater, based on a laboratory result in the past 3 months.
Main reasons for not taking part
- Currently using continuous glucose monitoring (CGM)
- Does not speak English
- Cannot attend the virtual DECIDE group
- Currently pregnant
- Currently on dialysis
Read by machine on 9 November 2026.
Where in United States
- Northwell HeathManhasset, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northwell Health
- Trial code
- NCT07743307
- Record updated
- 26 August 2026
- Original description
The purpose of this study is to determine if combining a virtual diabetes self-management program (DECIDE®) with continuous glucose monitoring (CGM) is practical and well-received by adults with type 2 diabetes. Twenty participants will attend the 9-week, virtual DECIDE Self-Management Program. They will receive CGM sensors to wear during the 22-week study to track their blood sugar. Participants will complete questionnaires at three time points -- at baseline, 1 week after the DECIDE Program ends, and 3 months after the DECIDE Program ends. They will also complete a blood draw to measure hemoglobin A1C at baseline and 3 months after the intervention ends. Additionally, they will complete a brief interview after the program ends to gather insights into participants' experiences with the program. The study aims to examine whether this integrated approach will be both feasible and acceptable, potentially leading to better diabetes management and improved health outcomes.Read full original descriptionShow less
Examining the Feasibility of Pairing a Diabetes Self-Management Program With Continuous Glucose Monitoring for Adults With Type 2 Diabetes
The purpose of this study is to determine if combining a virtual diabetes self-management program (DECIDE®) with continuous glucose monitoring (CGM) is practical and well-received by adults with type 2 diabetes. Twenty participants will attend the 9-week, virtual DECIDE Self-Management Program. They will receive CGM sensors to wear during the 22-week study to track their blood sugar. Participants will complete questionnaires at three time points -- at baseline, 1 week after the DECIDE Program ends, and 3 months after the DECIDE Program ends. They will also complete a blood draw to measure hemoglobin A1C at baseline and 3 months after the intervention ends. Additionally, they will complete a brief interview after the program ends to gather insights into participants' experiences with the program. The study aims to examine whether this integrated approach will be both feasible and acceptable, potentially leading to better diabetes management and improved health outcomes.
Inclusion: Aged 18 years or older; Diagnosis of type 2 diabetes; Suboptimal hemoglobin A1C (8.0% or greater) based on a laboratory result in the past 3 months; Access to and capability of using a smart cellular device; Smart cellular device compatible with the Freestyle Libre CGM smartphone application; Capable of giving informed consent.
Exclusion: Currently using CGM; Currently on dialysis; Non-English speaking; Unavailable to attend the virtual DECIDE group; Unavailable for follow-up; Currently pregnant.